A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum. The anticipated time of study treatment is until disease progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients with metastatic colon or rectal cancer, progressing or relapsing after first-line treatment;

• Women of childbearing potential must use adequate contraception up to at least 6 months after the last dose of bevacizumab.

Exclusion Criteria:

• Patients with metastatic colon or rectal cancer scheduled for a first-line systemic treatment;

• Untreated brain metastases, spinal cord compression or primary brain tumours;

• Pregnant or lactating women;

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study start;

• Treatment with any investigational drug, or participation in another investigational study, within 30 days prior to enrollment.